The burden of cancer in old age is increasing as a result from both the expanding number of older persons in the population and the high and still increasing cancer incidence in this group. The goal of this article is to outline the shortcomings and challenges of the management of cancer in the elderly. Several factors contribute to the complexity of this management, such as the enormous heterogeneity in this population, increased co-morbidity, reduced functional status, increased frailty and different treatment goals from those in younger patients. Other problems include the lack of data on the efficacy and toxicity of cancer treatment in this age group, the lack of awareness of life-expectancy and the lack of an easy applicable and validated frailty scale. Improvement of the quality of oncological care in this age group could be achieved by initiation of clinical trials specifically directed at the elderly, in which a frailty scale is implemented. The results of these trials may lead to more evidence-based decision making in cancer treatment in the elderly.
Currently over 60% of newly diagnosed cancers persons, the magnitude of the cancer burden in the occur in patients over 65 years of age [1] .
aged is clear. Survival data from 17 European This percentage is increasing as earlier in this countries demonstrated that elderly with cancer face decade 55% of all malignancies were identified in a worse prognosis than younger patients [3] . This this group, while about 20 years ago it was only 50% inferior prognosis may be the product of several [1] . Tumour registry data obtained in 1997 by the factors, such as differences in biological behaviour nine comprehensive cancer centres in our country of the tumour, decreased DNA-repair and age-related established that cancer is most common in the host factors as hormone receptors and circulating elderly, as 28% of new patients was aged between 65 hormone levels, and mostly these cannot be affected and 74 years and 30% was 75 years or older [2] . [4] . However, as least as important are the observed Combined with a still expanding number of older age-related differences in diagnostic procedures and therapy [5] [6] [7] [8] , upon which still is room for improvement. These age-related differences derive from both access to transportation, social support and the diagnostic procedures are performed. Some of these results of physiological decline, whereas doctor-reare patient-related while others are doctor-related lated factors include attitude, know-how, assump- [11, 12] . tions, generalizations and prejudice. Because of this, Examples of patient-related factors are ignorance the pro's and cons for diagnostic procedures and of (non-specific) symptoms or attributing them to treatment options in older patients are not always normal ageing or to co-morbid conditions. Other properly balanced. About 10-15% of the elderly factors are the assumption that cancer is contagious, experience an optimal ageing without occurrence of or the overwhelming idea that cancer is not a co-morbidity ('old and fit'). When cancer is diagtreatable disease. nosed in a person within this group, the calendar age Examples of doctor-related factors are the lack of should not be an argument in therapeutic decisions, knowledge of the normal proces of ageing and of and the first choice in oncological care should be the life-expectancy, stereotyped opinions, and therapeuprevailing standard treatment. However, in frail older tic nihilism. All these factors also contribute to patients counter-arguments about treatment can be referral filters, of which the exact magnitude and considerable, and decisions regarding treatment underlying mechanisms still have to be unraveled. should be weighed carefully. In this article we Older patients are probably less frequently referred outline our view with respect to optimal oncological to tertiary cancer centres, while differences in diagcare for older patients. Specific issues on medical nostic and therapeutic approach between tertiary treatment such as alterations in pharmaco-dynamics cancer centres and general hospitals are very likely. or pharmacokinetics are beyond the scope of this
In a retrospective study of ovarian cancer patients, review.
differences were observed in background and experience of surgeons: in the patient group over 80 years old, only 14% were treated by a gyneacologic Diagnostic procedures and filters for referral oncologist, 29% by an obstetrician / gynaecologist and 31% by a general surgeon [13] . These figures The basis of adequate oncological care comprises were 23, 56 and 14%, respectively for patients under careful diagnostic examinations followed by suffi-60 years. Another illustration of the existence and cient staging procedures, as stage governs both influence of referral filters are the results of a study treatment and prognosis. However, in older patients comparing performance status and co-morbidity in the diagnostic work-up is often less extensive comolder cancer patients ( . 70 years), younger cancer pared to their younger counterparts, so that there is a patients ( , 70 years) and non-cancer patients [14] . higher proportion of unstaged disease in the elderly Older cancer patients intriguingly exhibited a better [5] . It can be assumed that there is a similar functional status and less co-morbidity than older difference in diagnostic approaches in the preceding patients with non-neoplastic disease. In this study the phase in which a histological diagnosis has not been selection of patients probably influenced the results obtained. An essential key in diagnosing a disease is as the cancer patients were recruited from specialised a thorough physical examination. Although older cancer centres, whereas the non-cancer patients were patients visit a doctor more frequently than younger recruited from geriatric or general medicine departpatients, and consequently undergo more often a ments. In our country referral filters have been found general physical examination, the number of too. The variation in referral for postoperative gynecological examinations declines [9] . This could radiotherapy for endometrial carcinoma stage I was be the result of the misperception that older patients mainly determined by differences in opinion between might reject such examinations. In a survey regardreferring gynaecologists [15] . In prostate cancer ing the attitude of doctors and of older patients patients, the decision of urologists to use radical towards rectal examinations, the majority of patients prostatectomy was not only determined by patients' considered it an important examination and did not age and tumour characteristics, but also by the type find it disagreeable [10] . The varies between countries. Differences in incidence as specifically aimed at older cancer patients, who have well as percentage of histologically verified cancer been underrepresented in common cancer trials. For between neighbouring countries do not reflect example, the overall accrual in the South-West genuine differences but have to be attributed to Oncology Group trials between 1993 and 1996 for dissimilar management. If survival data are considpatients 65 years of older was only 25%, whereas the ered as endpoint for management, the lower survival corresponding proportion of cancer in the general for elderly, as well as younger patients, in Eastern population in this age group was 63% [19] . European countries compared to other European As well as age restrictions related to inclusion countries, probably reflects the difference in access criteria, other reasons elucidated for this underrepreto and quality of care [3] . The various management sentation are the exclusion due to co-morbidity, of cancer in old age not only results from disparity in advanced stage of disease, lower level of education, economical resources but also from another cultural the idea that older patients have less benefit from point of view. For example, the concept of 'Tenjuaggressive treatment, the lack of financial, social, Gann' or 'natural end cancer' has recently been and logistic support for participation in a trial as well advocated [17] . Tenju-gann is derived from the as low referral [20, 21] . Considering this underrepreJapanese words 'ten' which means heaven and 'ju' sentation of older patients, the interpretation of these which means 'celebrated long life' and considers the trials needs to be viewed with caution, because a development of cancer at very old ages as more or selection bias, including only the 'best' elderly, less inevitable. Sometimes the result may be a likely influences the results. peaceful death with minimal suffering. This concept, probably more accepted in non-Western countries, rejects aggressive treatment, but may also preclude Life-expectancy appropriate diagnostic procedures and therefore causes surrogate decisions [17, 18] .
During the last century, life-expectancy has graduIn our opinion, a proper approach to each older ally increased. For the Dutch population, the mean patient starts with a complete evaluation of the life-expectancy for a male septagunarian is 11 years, symptoms and signs, which have to be clarified for an octogenerian 6 years, and for a nonagenerian satisfactory, and in which the occurence of a maligit is still 3 years. For females these figures are even nancy always has to be considered. Referrals to more impressive, 15, 8 and 4 years, respectively medical specialists have to accomplished if neces- [21] . Against this, the variability of the life-expecsary. After the diagnosis of cancer has been contancy is increased, which decreases confidence of firmed histologically, or is thought to be very likely, individual predictions. The heterogeneity within the complementary diagnostic procedures are only warolder population, usually defined as everyone aged ranted when there are therapeutic consequences.
over 65 years, partly results from the wide age range. These therapeutic consequences, chemotherapy, In addition, the age at which patients are considered surgery, radiotherapy, were recently reviewed by 'elderly' varies in the literature. In geriatric medicine Turner et al. [7] . Those therapeutic consequences are often the limit of 65 years is mentioned, whereas in determined by the life-expectancy, contra-indications the European literature on cancer in the elderly often if any, as well as by the patients' acceptance of the the age limit of 70 years is used. Some authors treatment proposed.
advocate to distinguish the 'young old' (65-74 years), the 'older old' (75-84 years) and the 'oldest old' (85 years or older) [1] . Subdivision in age Lack of data groups is primarily important for research purposes, which secondarily can influence individual treatment A major obstacle in selecting the optimal cancer decisions. For example, after comparison of clinical treatment for older patients is the lack of sound data and histological characteristics and outcome of on the efficacy and toxicity of therapy, as well as on Dutch Non-Hodgkin lymphoma patients, patients quality of life. This is because few studies are with indolent lymphoma are considered 'elderly' when they are older than 70 years whereas in conditions with increasing age was observed in aggressive lymphoma this occurs when patients are colorectal and prostate cancer patients in our country older than 65 years [22] . The life-expectancy is [16, 26] . The assessment of co-morbidity is important crucial in decisions regarding oncological treatment.
for decisions regarding treatment and the expected For example, in a 90-year-old person suffering from toxicity profile, but has also implications for proga bowel obstruction due to a sigmoid tumour, a nosis. The number of co-morbidities were predictive surgical resection will be performed as the profit and of early mortality in colon-and breast cancer loss account will in the short term go in favour of [27, 28] . In breast cancer patients suffering from three profit. However, when the histological examination or more concomitant diseases the all cause mortality reveals a Dukes-C colon carcinoma, no adjuvant appeared 4-fold higher than in the patients without chemotherapy will be proposed because any benefit comorbid conditions [28] . In Dutch colorectal cancer manifests after several years [23] .
patients, co-morbidity did not affect the resection rate but did negatively influence short-term survival [26] .
Co-morbidity
A consequence of the enhanced co-morbidity is the accompanying, often abundantly provided, coNext to life-expectancy, co-morbidity deserves medication. A cross-sectional study in three general attention. In the Netherlands, the increase in lifepractices in the Netherlands showed that one third of expectancy observed between 1983 and 1994 is all patients aged over 65 years used two ore more mainly based on an increase of 'unhealthy years', drugs [29] . This polypharmacy can lead to drug although the severity of this 'ill health' declined interactions interfering with cytotoxic agents, and [21]. The rise in unhealthy life-expectancy particutherefore should be considered in terms of treatment larly is related to the corresponding increase in decisions. age-dependent diseases, whose pathogenesis directly involves normal ageing [24] . Examples are cardiovascular diseases, osteoporosis and Alzheimers' disFunctional status ease. The incidence and prevalence of these agedependent diseases gradually increase with ageing, Ageing is often associated with a decline in and in many cases the transition between physiologifunctional status, which refers to the ability to cal ageing and age-dependent disease is ill-defined.
perform tasks, and includes basic activities of daily They form a major part of co-morbidity and strongly life (BADL) such as eating, bathing, dressing and influence life-expectancy, quality of life and frailty movement but also more complex activities such as as well as decisions regarding treatment.
using the telephone, shopping, housekeeping, handTumour registry data for 7600 cancer patients in ling finances (instrumental activities of daily life, the United States showed in patients aged between IADL). In a Danish cross sectional study, the phys-55-64, 65-74 and over 75 an increase in the mean ical abilities evaluated by changes in activities of number of co-morbidities from 2.9 to 3.6 and 4.2 [1] .
BADL gradually inclined with ageing without levelIn contrast, the number of patients without any coling off [30] . Functional limitations, low physical morbidity declined in these groups from about 10 to activity as well as cognitive impairment have been 6% and 4%, respectively. In a Dutch series of 3864 identified as risk factors for receiving inadequate lung cancer patients, the prevalence of co-morbidity treatment for cancer [31] . Cancer in itself is associwas higher in patients aged over 70 years (69%) ated with impairment in BADL and IADL, but these compared with patients aged below 70 years (52%) reductions are less important than the limitations [25] . The most frequent concomitant diseases were observed in other chronic conditions such as iscardiovascular (23%), chronic obstructive pulmonary chaemic heart disease, chronic pulmonary disease disease (22%), other malignancies (15%), hypertenand rheumatoid arthritis [32] . sion (12%) and diabetes mellitus (7% tional status is often assessed by the Karnofsky score ised patients [37] . Rockwood et al. reported a doseor the ECOG performance score, which are known response curve between frailty and institutionalisafor their predictive value for outcome. However, tion as well as survival with their frailty scale, which these quite crude scales probably underrate funcprobably under-rates psychosocial issues [43] . tional impairment in older persons. Second, physical
In geriatric oncology often the frailty definition functioning prior to the diagnosis appeared to be a according to Balducci is used (Table 1 ) [44] . predictor of physical functioning during and after This definition is for rapid screening very helpful, treatment in geriatric cancer patients [33] . Last, although a few comments can be made. In our physicians underestimate the functional disabilities opinion, age over 85 years should be considered and psychological problems of their patients [34, 35] . more as a risk factor for frailty than as an absolute criteria. Prospective data using this frailty scale in cancer patients are not yet available, although some of the items proved predictors of survival. The frailty Frailty definition does not include a grading of the severity of frailty, which could be helpful for individual In geriatrics, the judgment of the 'general contreatment decisions. dition', considering multiple domains prevails.
For these reasons, an easy applicable, validated Frailty is a metaphysical notion implying this assessment of frailty is urgently required. After 'general condition'. The frailty concept is an umbrelimplementation in clinical trials, this assessment la, covering multiple domains, such as co-morbidity, could guide decisions regarding anti-cancer treatfunctional and sensory impairment, incontinence, ment. In case of recording a frailty score below a mobility, falls, nutrition, cognitive functioning, psycertain level A, treatment will be beneficial and chological factors and social support [36] [37] [38] . Until coincide with acceptable toxicity, while in case of a now, no agreement has been accomplished about the frailty score above a certain level B, treatment will ultimate definition of frailty. Moreover, a valid be unwise. In case of a frailty score between A and assessment of frailty is still lacking.
B, treatment can be considered, but intensive supporCo-morbidity and functional status are important tive care measures have to be taken. determinants in cancer treatment with respect to Besides the prediction of efficacy and toxicity, this efficacy, toxicity and survival, as discussed above.
brief frailty assessment could even be a predictor of Previously, they appeared independent variables in survival. The frailty value could be evaluated reguolder cancer patients, and should be measured separlarly, because several determinants can be influenced ately [39] .
by interventions, such as nutrition. However, one might question whether the the Karnofsky or WHO-scales used in oncological research for functional status are sensitive enough for Cultural factors influence quality of life and especialfrom younger patients in acceptance of agressive ly in multicentre studies this might confuse results chemotherapy aiming either cure or palliation, but [54] . Generally, symptom relief is highly valued and were less willing to accept toxicity (with negative is usually associated with improvement of quality of impact on quality of life) for survival time [45] .
life [55] . In optimal oncological care, the quality of Bremmes et al. [46] sketched a hypothetical situation life at presentation and the patients' expectations and to untreated cancer patients at their first admission desires about their lives have to be elucidated before for receiving chemotherapy. ''You have been retreatment is started and probably even before far ferred to our oncological unit for treatment of a reaching examinations have been arranged. In case malignant tumour. The treatment is toxic and has of abandoning anti-tumour therapy, adequate pallianumerous side-effects and drawbacks''. tive care should be provided. Paralleling differences Patients under 40 years would accept this toxic in cancer treatment, differences in palliative care treatment with hardly any benefit such as the reducbetween age groups have been recognized, in which tion of symptoms (8%), life prolongation (3 months) older patients often come off badly compared to and chance of cure (7%). In contrast, patients older younger patients [6, 56] . than 60 years accepted this treatment only for a 50% chance of reduction of symptoms, a life prolongation of 12 months and a chance of cure of 50%. When a Future perspectives comparable hypothetical case was proposed to lung cancer patients who previously received chemother-
The issue of oncological care in old age is apy, again a difference in minimal survival threshold extensive and complex, and requires more attention for acceptance of treatment was established, namely and education of health care staff [7] . Oncologists 4.5 months for patients younger than 60 years and 9
should be aware of the pros and cons of cancer months for patients older than 70 years [47] . In this treatment, which in turn should be assessed by study, also a choice was given between chemovalidated instruments. It is to be hoped that a frailtytherapy and supportive care. Remarkably, only 22% indicator will be developed, which can be imof all patients chose chemotherapy, in the group of plemented in oncological research. patients younger than 60 years 65% chose supportive Challenges for research comprise studies directed care and in the patients older than 70 years this specifically at older patients. In these studies, geriatpercentage increased to 85%. These kind of studies ric and frailty assessments should be taken along have not only been performed in settings using with quality of life as a primary endpoint. This chemotherapy. Among 148 patients with prostate should provide grounds for treatment decisions, and cancer 26% preferred surveillance over surgery even lead to evidence-based geronto-oncology. However, when there was a small 10-years benefit of surgery because of the enormous heterogeneity in the older [48] .
population, the evidence achieved will not unequivoFortunately quality of life assessments receive cally correspond with the best treatment for the increasing attention. Frequently used and validated individual patient. Patients will still require some scales are the EORTC QLQ-C30, the FACT scale individual balancing of treatment options. and the Rotterdam symptom check list [49] [50] [51] [52] .
Leading on from the fact that oncological care to, However, the interpretation of data obtained by only a few, children is provided by special peadiatric surveys of quality of life need some consideration oncologists, we advocate the emergence of special and pitfalls can be recognized. Statistically signifigeronto-oncologists, in the first instance for academ- 
